Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally
5.1.2021 16:00:00 EET | Business Wire | Press release
MyHeritage, the leading global platform for discovering your past and empowering your future, announced today that it is sponsoring a racing team in the 2021 Dakar Rally — the elite off-road endurance competition currently taking place in Saudi Arabia. The MyHeritage team comprises driver Danny Pearl, a veteran of off-road racing, and navigator Charly Gotlib, who has participated in the Dakar Rally more than 30 times over the years, and has received an honorary distinction of Dakar Legend from the race organizers. The team is managed by Omer Pearl, Danny’s son. In recent years, Omer has managed the Pearl Racing Team in different competitions around the world. The team is named the MyHeritage Team and is competing in the Dakar’s Lightweight Vehicle category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005542/en/
Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally (Photo: Business Wire)
As the international market leader for exploring family history and finding relatives, MyHeritage develops innovative search and matching technologies and has a global database of historical records to help millions of people connect to their family history. Sponsoring a team led by a father-son duo is par for the course for MyHeritage. The company has a long history of partnering with top athletes, sports teams, and cultural figures to reveal their family history, forge connections with their relatives, and underscore the importance of knowing one’s roots.
Danny and Omer Pearl founded the Pearl Racing Team out of their passion for motorsports. The team has competed for many years in the SSV category, racing in numerous international competitions.
The Dakar Rally is considered the toughest and most grueling off-road competition in the world. This is the second year the competition is being held in Saudi Arabia, following its relocation from South America, where it was held for the last decade. The race spans more than 7,000 kilometers and 12 days over the challenging and beautiful Saudi terrain. This year’s race departed from Jeddah and will traverse the entire Arabian desert in a circular course. Each day the team will navigate under the most extreme conditions, using a Road Book produced by the rally organizer.
“As leaders in the field of exploring and discovering family history, we are thrilled to support a team that includes a father and son who are competing in one of the world’s most difficult competitions,” said Gilad Japhet, Founder and CEO of MyHeritage. “Particularly during these challenging times, we appreciate the significance of supporting family members coming together in bold and creative ways, working as a team to achieve the impossible. Just like the Dakar, family history can be an enjoyable and adventurous journey.”
“It is with great pride and excitement that we enter this legendary race,” said Omer Pearl. “We believe that determination and perseverance yield results, and our family bond is one of the driving forces behind our success. We hope that our efforts will inspire more families to team up and work together to pursue their dreams.”
The Dakar Rally is taking place between January 3–15, 2021.
About MyHeritage
MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. Launched in 2016, MyHeritage DNA has become one of the world’s largest consumer DNA databases, with more than 4.6 million customers. Since 2020, MyHeritage is home to the world’s best technologies for enhancing and colorizing historical photos. MyHeritage is the most popular DNA test and family history service in Europe. www.myheritage.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005542/en/
Contact information
MyHeritage
Rafi Mendelsohn
Director of PR & Social Media
Phone: 917-725-5018
Email: pr@myheritage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom